The Oil & Gas Journal, first published in 1902, is the world's most widely read petroleum industry publication. OGJ delivers international oil and gas industry news; analysis of issues and events; practical technology for design, operation, and maintenance of oil and gas operations; and important statistics on energy markets and industry activity.

OGJ is edited to meet the needs of engineers, geoscientists, managers, and executives throughout the oil and gas industry. It is part of Endeavor Business Media, Nashville, Tenn., which also publishes Offshore Magazine.

Endeavor Business Media’s Petroleum Group also produces targeted e-Newsletters; hosts global conferences and exhibitions, seminars, and forums; and publishes directories, technical books, print and electronic databases, surveys, and maps.

Additional Information

Website & Technical Help

For help with subscription purchases or refunds, or trouble logging into the paid subscription content on www.ogj.com, please contact Customer Service at [email protected] or call 1-847-559-7598.

For more customer service information, please click here.

Bionoid Pharma, Inc. Provides Corporate Update and Outlines Growth Strategy for 2025

NEW YORK CITY, NEW YORK / ACCESSWIRE / January 14, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to provide a corporate update as it looks ahead to a promising year in 2025. The company remains committed to its strategic growth plan, which centers on acquiring revenue-positive e-commerce websites and integrating advanced AI technology to drive expansion in the health and wellness sector.

Bionoid's proprietary AI Maverick Intel platform will play a pivotal role in the company's growth strategy. This cutting-edge AI-driven marketing system is designed to enhance customer engagement, optimize advertising efficiency, and deliver tailored user experiences. By leveraging AI Maverick Intel, Bionoid aims to maximize the potential of its e-commerce platforms and solidify its position as an innovator in the industry.

"Our vision for 2025 is focused on scaling our operations through strategic acquisitions and harnessing the power of AI technology," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "AI Maverick Intel is a cornerstone of our strategy, enabling us to deliver unparalleled customer experiences while driving sustainable growth and profitability."

Bionoid plans to expand its portfolio with high-value, revenue-generating e-commerce websites in the health and wellness sector, ensuring each acquisition aligns with its long-term objectives. The company is confident its continued focus on innovation and strategic execution will deliver strong results for its stakeholders in the coming year.

About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding its revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform supports the company's mission to deliver innovative, AI-driven solutions that foster customer loyalty, operational excellence, and sustainable growth.

Stay connected:

For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: bionoidpharma@gmail.com

SOURCE: Bionoid Pharma, Inc.



View the original press release on accesswire.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.